

Alain C Mita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4974817/publications.pdf>

Version: 2024-02-01

67
papers

3,529
citations

257450

24
h-index

155660

55
g-index

68
all docs

68
docs citations

68
times ranked

6584
citing authors

#	ARTICLE	IF	CITATIONS
1	Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, in Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2117-2124.	1.6	538
2	Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 723-730.	7.0	314
3	LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. <i>Cell</i> , 2018, 172, 825-840.e18.	28.9	312
4	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer. <i>JAMA Oncology</i> , 2019, 5, 393.	7.1	303
5	Combined autophagy and HDAC inhibition. <i>Autophagy</i> , 2014, 10, 1403-1414.	9.1	240
6	Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 3157-3163.	7.0	207
7	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4888-4897.	7.0	181
8	Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5533-5533.	1.6	117
9	Incidence of Oropharyngeal Cancer Among Elderly Patients in the United States. <i>JAMA Oncology</i> , 2016, 2, 1617.	7.1	114
10	Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer. <i>Cancer</i> , 2017, 123, 3933-3942.	4.1	108
11	Association of Quantitative Metastatic Lymph Node Burden With Survival in Hypopharyngeal and Laryngeal Cancer. <i>JAMA Oncology</i> , 2018, 4, 985.	7.1	82
12	Quantitative survival impact of composite treatment delays in head and neck cancer. <i>Cancer</i> , 2018, 124, 3154-3162.	4.1	68
13	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30.		68
14	A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. <i>Oncology</i> , 2019, 97, 102-111.	1.9	67
15	Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2017, 76, 36-44.	2.8	64
16	Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 53-62.	2.5	64
17	Cabazitaxel: More Than a New Taxane for Metastatic Castrate-Resistant Prostate Cancer?. <i>Clinical Cancer Research</i> , 2012, 18, 6574-6579.	7.0	48
18	Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics. <i>Targeted Oncology</i> , 2017, 12, 623-641.	3.6	47

#	ARTICLE	IF	CITATIONS
19	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.. Journal of Clinical Oncology, 2016, 34, 4009-4009.	1.6	42
20	Facility Volume and Survival in Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 408-417.	0.8	37
21	Comparison of Survival After Transoral Robotic Surgery vs Nonrobotic Surgery in Patients With Early-Stage Oropharyngeal Squamous Cell Carcinoma. JAMA Oncology, 2020, 6, 1555.	7.1	36
22	Human papillomavirus-associated oropharyngeal cancer among patients aged 70 and older: Dramatically increased prevalence and clinical implications. European Journal of Cancer, 2018, 103, 195-204.	2.8	30
23	Bromodomain inhibitors a decade later: a promise unfulfilled?. British Journal of Cancer, 2020, 123, 1713-1714.	6.4	30
24	Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. Cancer Research, 2021, 81, 6273-6280.	0.9	30
25	Predictors of survival in head and neck mucosal melanoma. Oral Oncology, 2017, 73, 36-42.	1.5	26
26	Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.. Journal of Clinical Oncology, 2016, 34, 367-367.	1.6	26
27	Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base. Cancer, 2017, 123, 4583-4593.	4.1	23
28	A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS ONE, 2019, 14, e0221994.	2.5	23
29	Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. Investigational New Drugs, 2017, 35, 616-626.	2.6	22
30	Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC).. Journal of Clinical Oncology, 2016, 34, 2516-2516.	1.6	22
31	Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas. Oncotarget, 2017, 8, 86769-86783.	1.8	21
32	A multicenter study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.. Journal of Clinical Oncology, 2018, 36, 2578-2578.	1.6	19
33	Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase Ib trial: Analysis of safety, clinical activity, and PD-L1 expression.. Journal of Clinical Oncology, 2016, 34, 4514-4514.	1.6	18
34	Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus. Molecular Cancer Therapeutics, 2015, 14, 1404-1413.	4.1	17
35	Postoperative chemoradiotherapy in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension and the influence of nodal classification. Head and Neck, 2018, 40, 1228-1236.	2.0	15
36	Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial. , 2021, 9, e002998.		14

#	ARTICLE	IF	CITATIONS
37	Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer. <i>Cancer</i> , 2017, 123, 1555-1565.	4.1	12
38	Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case. <i>JCO Precision Oncology</i> , 2020, 4, 614-619.	3.0	11
39	Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?. <i>Cancer</i> , 2020, 126, 58-66.	4.1	10
40	Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3095-3095.	1.6	10
41	Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 530-539.	2.4	9
42	Impact of insurance on survival in patients >65 with head & neck cancer treated with radiotherapy. <i>Clinical Otolaryngology</i> , 2020, 45, 63-72.	1.2	9
43	Nodal staging convergence for HPV ⁻ and HPV ⁺ oropharyngeal carcinoma. <i>Cancer</i> , 2021, 127, 1590-1597.	4.1	8
44	Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer. <i>Targeted Oncology</i> , 2020, 15, 523-530.	3.6	7
45	Variations in the association of grade with survival across the head and neck cancer landscape. <i>Head and Neck</i> , 2021, 43, 1105-1115.	2.0	7
46	Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3084-3084.	1.6	7
47	523...Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors. , 2021, 9, A553-A553.		7
48	Phase 1b study of the novel first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-relapsed and refractory solid malignancies and dose escalation update.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2574-2574.	1.6	7
49	Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8564-8564.	1.6	6
50	Perspectives in Head and Neck Medical Oncology. <i>Cancer Treatment and Research</i> , 2018, 174, 163-185.	0.5	5
51	Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence. <i>Oral Oncology</i> , 2019, 99, 104472.	1.5	5
52	Quantitative Nodal Burden and Mortality Across Solid Cancers. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1003-1011.	6.3	4
53	Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 339-351.	2.3	2
54	The role of concomitant chemoradiotherapy in AJCC 7th edition T1-2N1 oropharyngeal carcinoma in the human papillomavirus era. <i>Oral Oncology</i> , 2020, 110, 104882.	1.5	2

#	ARTICLE	IF	CITATIONS
55	469â€¦..A phase 1 first in human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies. , 2021, 9, A498-A498.		2
56	Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Investigational New Drugs, 2019, 37, 76-86.	2.6	1
57	Phase 1b of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with etoposide and cisplatin (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).. Journal of Clinical Oncology, 2014, 32, 7601-7601.	1.6	1
58	525â€¦..Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors. , 2021, 9, A555-A555.		1
59	A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.. Journal of Clinical Oncology, 2022, 40, 9085-9085.	1.6	1
60	Phase I study of cabazitaxel (Cbz) plus cisplatin (Cis) in patients (pts) with advanced solid tumors: Substudy to evaluate the impact of a strong CYP3A inhibitor (ketoconazole; K) or inducer (rifampicin;) Tj ETQq0 0 0.0 BT /Overlock 10 T		
61	Pharmacokinetic study of aldoxorubicin in solid tumor patients.. Journal of Clinical Oncology, 2013, 31, e13572-e13572.	1.6	0
62	Pharmacokinetic study of aldoxorubicin in solid tumor patients.. Journal of Clinical Oncology, 2014, 32, e13557-e13557.	1.6	0
63	The effect of tivantinib on QTc interval in subjects with advanced solid tumors and healthy subjects.. Journal of Clinical Oncology, 2014, 32, e13528-e13528.	1.6	0
64	Phase 1b study of aldoxorubicin + gemcitabine in metastatic solid tumors.. Journal of Clinical Oncology, 2016, 34, 2523-2523.	1.6	0
65	Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET).. Journal of Clinical Oncology, 2016, 34, 4095-4095.	1.6	0
66	Correlation of pathologic tumor grade with survival in oral cavity squamous cell carcinoma.. Journal of Clinical Oncology, 2020, 38, e18557-e18557.	1.6	0
67	Phase 1 study of OBT076, a first-in-class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy, and PK/PD results.. Journal of Clinical Oncology, 2022, 40, 3028-3028.	1.6	0